Treatment of glioblastoma in "elderly" patients

Susannah Yovino, Stuart A Grossman

Research output: Contribution to journalArticle

Abstract

The number of patients over 65 with newly diagnosed glioblastoma is anticipated to increase significantly in coming decades as a result of demographic shifts in the United States. Older patients with this disease have a significantly worse life expectancy compared with patients under 65. Mounting clinical evidence suggests that fit elderly patients with glioblastoma benefit from the addition of temozolomide to standard surgery and radiation. As a result, for healthy patients over 65 we recommend maximal surgical debulking followed by involved-field radiotherapy (60 Gy in 30 fractions) with concurrent temozolomide (75 mg/m 2/day) and 6 months of adjuvant temozolomide (150-200 mg/m 2/day for five consecutive days/month). Patients over 65 with newly diagnosed or recurrent glioblastoma should also be considered for inclusion in clinical trials. MGMT is a validated prognostic marker in patients over 65 and may be useful in clinical decision-making in frail elderly patients. Age alone should not be a factor in deciding how patients with newly diagnosed glioblastoma should be treated.

Original languageEnglish (US)
Pages (from-to)253-262
Number of pages10
JournalCurrent Treatment Options in Oncology
Volume12
Issue number3
DOIs
StatePublished - Sep 2011

Fingerprint

Glioblastoma
temozolomide
Therapeutics
Frail Elderly
Life Expectancy
Radiotherapy
Demography
Clinical Trials
Radiation

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Treatment of glioblastoma in "elderly" patients. / Yovino, Susannah; Grossman, Stuart A.

In: Current Treatment Options in Oncology, Vol. 12, No. 3, 09.2011, p. 253-262.

Research output: Contribution to journalArticle

@article{0644e01b803d41c59fbfe5c4784c57be,
title = "Treatment of glioblastoma in {"}elderly{"} patients",
abstract = "The number of patients over 65 with newly diagnosed glioblastoma is anticipated to increase significantly in coming decades as a result of demographic shifts in the United States. Older patients with this disease have a significantly worse life expectancy compared with patients under 65. Mounting clinical evidence suggests that fit elderly patients with glioblastoma benefit from the addition of temozolomide to standard surgery and radiation. As a result, for healthy patients over 65 we recommend maximal surgical debulking followed by involved-field radiotherapy (60 Gy in 30 fractions) with concurrent temozolomide (75 mg/m 2/day) and 6 months of adjuvant temozolomide (150-200 mg/m 2/day for five consecutive days/month). Patients over 65 with newly diagnosed or recurrent glioblastoma should also be considered for inclusion in clinical trials. MGMT is a validated prognostic marker in patients over 65 and may be useful in clinical decision-making in frail elderly patients. Age alone should not be a factor in deciding how patients with newly diagnosed glioblastoma should be treated.",
author = "Susannah Yovino and Grossman, {Stuart A}",
year = "2011",
month = "9",
doi = "10.1007/s11864-011-0158-0",
language = "English (US)",
volume = "12",
pages = "253--262",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Treatment of glioblastoma in "elderly" patients

AU - Yovino, Susannah

AU - Grossman, Stuart A

PY - 2011/9

Y1 - 2011/9

N2 - The number of patients over 65 with newly diagnosed glioblastoma is anticipated to increase significantly in coming decades as a result of demographic shifts in the United States. Older patients with this disease have a significantly worse life expectancy compared with patients under 65. Mounting clinical evidence suggests that fit elderly patients with glioblastoma benefit from the addition of temozolomide to standard surgery and radiation. As a result, for healthy patients over 65 we recommend maximal surgical debulking followed by involved-field radiotherapy (60 Gy in 30 fractions) with concurrent temozolomide (75 mg/m 2/day) and 6 months of adjuvant temozolomide (150-200 mg/m 2/day for five consecutive days/month). Patients over 65 with newly diagnosed or recurrent glioblastoma should also be considered for inclusion in clinical trials. MGMT is a validated prognostic marker in patients over 65 and may be useful in clinical decision-making in frail elderly patients. Age alone should not be a factor in deciding how patients with newly diagnosed glioblastoma should be treated.

AB - The number of patients over 65 with newly diagnosed glioblastoma is anticipated to increase significantly in coming decades as a result of demographic shifts in the United States. Older patients with this disease have a significantly worse life expectancy compared with patients under 65. Mounting clinical evidence suggests that fit elderly patients with glioblastoma benefit from the addition of temozolomide to standard surgery and radiation. As a result, for healthy patients over 65 we recommend maximal surgical debulking followed by involved-field radiotherapy (60 Gy in 30 fractions) with concurrent temozolomide (75 mg/m 2/day) and 6 months of adjuvant temozolomide (150-200 mg/m 2/day for five consecutive days/month). Patients over 65 with newly diagnosed or recurrent glioblastoma should also be considered for inclusion in clinical trials. MGMT is a validated prognostic marker in patients over 65 and may be useful in clinical decision-making in frail elderly patients. Age alone should not be a factor in deciding how patients with newly diagnosed glioblastoma should be treated.

UR - http://www.scopus.com/inward/record.url?scp=80054989813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054989813&partnerID=8YFLogxK

U2 - 10.1007/s11864-011-0158-0

DO - 10.1007/s11864-011-0158-0

M3 - Article

C2 - 21655911

AN - SCOPUS:80054989813

VL - 12

SP - 253

EP - 262

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 3

ER -